about
Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers.High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE"."Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the ClinicTargeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab.Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation.Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.Improving mutation notification when new genetic information is identified in research: a trial of two strategies in familial breast cancer.Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.A community-based model of rapid autopsy in end-stage cancer patients.Whole-genome characterization of chemoresistant ovarian cancer.Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.Monoclonal antibody CI-panHu defines a pan-human cell-surface antigen unique to higher primates.Biobanking in Cancer ResearchAltered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohortThe kConFab experience – 14 years of biobanking.RAD21 overexpression is frequently observed in BRCA-X Prostate CancersDecreased Prostate Cancer-Specific Survival of Men withBRCA2 Mutations from Multiple Breast Cancer FamilieskConFab: A Familial Breast Cancer Consortium Facilitating Research and Translational OncologyBiochemical characterization of the monoclonal antibody-defined ovarian carcinoma-associated antigen SGAThe sebaceous gland antigen defined by the OM-1 monoclonal antibody is expressed at high density on the surface of ovarian carcinoma cellsClinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomyOverexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancerHistopathological features of breast cancer in carriers of ATM gene variants
P50
Q33588213-2326723D-DED5-4945-AF85-658610400875Q34433513-93C96109-5F63-43E5-B426-2F0ACCA654E3Q34480599-E3DC4762-9E62-4A36-AD91-2FF65AF6B612Q36233893-20420B86-96E2-49D6-893A-51C439343D68Q36416071-FA684FD0-BA9D-4762-B235-0E24C45041FCQ37025837-66B29195-55A5-496B-A6EA-2E8D538B4D3EQ37410693-746E29E7-640A-45E1-8BBA-2C212AAA6773Q37525477-30184E19-A147-4704-A3CB-F8E904FFC321Q37581351-6939CFA1-2947-4BF7-9140-78A913911F2CQ38426753-44CEA105-DB26-4B48-B1CD-01A0E30A30FCQ42457867-C155DD64-B8E6-4DF2-8000-A3E23A1C76CEQ46957087-7A586945-5A4E-47D6-9243-B51F29CC606DQ48244745-90D366B7-1C29-4F07-B2E0-4CE797E69DD0Q48360452-8FD5EF7A-72CC-4C50-9782-863E9E717496Q50272478-54D11DEB-6863-4F10-8AC7-3785AC5ABEE4Q50548721-FC8EDE2F-D505-4178-B112-987E948FD2ACQ50638983-09395268-681F-403E-AFEF-BAA1F24DC064Q53182487-643FEF39-4921-45DC-BE54-C3D5B6612F35Q54430975-6095557F-355C-49F8-B906-F0672D2436F5Q54686144-A739BD8C-B16F-4602-B071-2A39DAC92B23Q54687088-6FD2C1BF-5168-4798-AE34-B643C5525147Q55265487-D30D9192-8D45-4C4F-BD92-7D024D5196EEQ59270784-F3D29D37-F644-4C2A-97E3-F93829758B63Q60013009-6CCFD8BA-8E79-416C-B322-4BBEBB070B70Q60013054-9BA740D5-A936-48D6-AB8F-11AAB05E3F49Q69490446-19704557-6E4F-4A91-AF9E-92E02679C2E7Q70109489-DC2736B8-2435-4D62-9498-BD8435990BBFQ73666921-ED1A8FB3-7D58-4C84-8B5F-28148DF29E83Q78553663-61B46B2C-54D0-4B3A-B12E-199141EB5F40Q79299773-04F649CC-70F7-4F68-A85C-7B23CCC369C8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Heather Thorne
@ast
Heather Thorne
@en
Heather Thorne
@es
Heather Thorne
@nl
Heather Thorne
@sl
type
label
Heather Thorne
@ast
Heather Thorne
@en
Heather Thorne
@es
Heather Thorne
@nl
Heather Thorne
@sl
prefLabel
Heather Thorne
@ast
Heather Thorne
@en
Heather Thorne
@es
Heather Thorne
@nl
Heather Thorne
@sl
P106
P31
P496
0000-0003-3610-2511